|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Taysha Gene Therapies, Inc. (TSHA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
272,790,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Co. owns the exclusive worldwide rights to a clinical-stage, intrathecally dosed AAV9 gene therapy program, known as TSHA-120, for the treatment of giant axonal neuropathy (GAN). GAN is a rare autosomal recessive disease of the central and peripheral nervous systems caused by loss-of-function gigaxonin gene mutations. TSHA-120 is an AAV9 self-complementary viral vector encoding the full length human gigaxonin protein.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
750,000 |
750,000 |
2,183,333 |
| Total Buy Value |
$0 |
$2,062,500 |
$2,062,500 |
$5,225,499 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
311,545 |
311,545 |
311,545 |
311,545 |
| Total Sell Value |
$963,903 |
$963,903 |
$963,903 |
$963,903 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
3 |
3 |
3 |
3 |
| End Date |
2025-07-20 |
2025-04-18 |
2024-10-18 |
2023-10-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-09-10 |
4 |
AS |
$3.23 |
$646,000 |
D/D |
(200,000) |
1,006,439 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-09-10 |
4 |
OE |
$0.70 |
$28,760 |
D/D |
41,150 |
1,206,439 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-21 |
4 |
S |
$2.85 |
$155,299 |
D/D |
(54,491) |
1,187,603 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-08-21 |
4 |
S |
$2.85 |
$162,604 |
D/D |
(57,054) |
1,165,289 |
|
- |
|
| Stalfort Sean |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
1,155,224 |
|
- |
|
| Donenberg Philip B |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
219,954 |
|
- |
|
| Long Alison S |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
105,843 |
|
- |
|
| Sepp-Lorenzino Laura |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
105,843 |
|
- |
|
| Manning Paul B |
|
– – • |
2025-05-30 |
4 |
B |
$2.75 |
$2,062,500 |
I/I |
750,000 |
2,841,704 |
0.01 |
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-03-11 |
4 |
D |
$1.69 |
$50,435 |
D/D |
(29,843) |
1,242,094 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
324,500 |
1,222,343 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
431,000 |
1,271,937 |
|
- |
|
| Nolan Sean P. |
Chief Executive Officer |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
892,500 |
2,078,358 |
|
- |
|
| Manning Paul B |
|
– – • |
2024-06-27 |
4 |
B |
$2.25 |
$2,999,999 |
D/D |
1,333,333 |
1,333,333 |
0.01 |
- |
|
| Donenberg Philip B |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
163,331 |
|
- |
|
| Long Alison S |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
49,220 |
|
- |
|
| Stalfort Sean |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
1,098,601 |
|
- |
|
| Sepp-Lorenzino Laura |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
49,220 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-02 |
4 |
D |
$1.51 |
$1,945 |
D/D |
(1,288) |
840,937 |
|
- |
|
| Alam Kamran |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
590,413 |
842,225 |
|
- |
|
| Nolan Sean P. |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,184,688 |
1,185,858 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
863,617 |
897,843 |
|
- |
|
| Manning Paul B |
10% Owner |
– – • |
2023-11-17 |
4 |
B |
$1.63 |
$163,000 |
I/I |
100,000 |
16,566,667 |
1.5 |
- |
|
| Alam Kamran |
Chief Financial Officer |
• – – |
2023-08-24 |
4 |
AS |
$2.33 |
$76,890 |
D/D |
(33,000) |
258,042 |
|
- |
|
| Manning Paul B |
10% Owner |
– – • |
2023-08-16 |
4 |
B |
$0.90 |
$14,820,000 |
I/I |
16,466,667 |
16,466,667 |
1.5 |
- |
|
77 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
